title: Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.
authors.forename: H-A
authors.initials: HA
authors.lastname: Hou
authors.forename: L-I
authors.initials: LI
authors.lastname: Lin
authors.forename: C-Y
authors.initials: CY
authors.lastname: Chen
authors.forename: H-F
authors.initials: HF
authors.lastname: Tien
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics*; D004252:DNA Mutational Analysis; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality; D009154:Mutation; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D022762:CCAAT-Enhancer-Binding Proteins; C515848:CEBPA protein, human